Login to Your Account


ACADIA PHARMACEUTICALS' DOUBLE WIN

Acadia Pharmaceuticals Inc. started the week with a double win: preparations to launch its lead product, Nuplazid, and a first FDA approval in the indication: treatment of hallucinations and delusions associated with PDP.

more »


Our Habitat for All Things Science
B-cell receptor could be antitumor target

Peptibodies targeting the B-cell receptor might provide a cancer therapy that is personalized to specific tumor cells but can be produced in a relatively automated fashion, making the production of such individualized therapy a realistic possibility.

Preclinical work describing the approach appeared in the April 25, 2016, online issue of the Proceedings of the National Academy of Sciences.

B cells have a truly unique surface protein – their business end, the B-cell receptor or idiotype, which is different on every B cell.

On B cell-derived tumor cells, that READ MORE »

Opinion


Partners in Focus